🇺🇸 FDA
Pipeline program

CSJ117

CCSJ117A12201E1

Phase 2 small_molecule terminated

Quick answer

CSJ117 for Asthma is a Phase 2 program (small_molecule) at Novartis Pharmaceuticals with 2 ClinicalTrials.gov record(s).

Program details

Company
Novartis Pharmaceuticals
Indication
Asthma
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials